Nimbus has appointed Merck & Co’s Donald Nicholson as the company’s new CEO.
Nicholson spent 26 years at Merck holding various strategic leadership and operational roles in diverse therapeutic areas including respiratory inflammation immunology bone endocrine urology infectious diseases and neurosciences.
He began his career in 1988 at the Merck-Frost Centre for Therapeutic Research in Montreal.
In his new role at Nimbus Nicholson will lead a US biotech with a portfolio of programmes in immunology oncology and metabolic diseases targeting mechanisms that have been traditionally difficult or intractable. The company is expected to enter human clinical trials in early 2015.
It is thrilling to join the company at such a watershed moment as the lead programs move toward clinical development,” said Dr Nicholson. “I look forward to working with such a highly respected team of colleagues Board members and investors to deliver the greatest value of the portfolio to patients.”